Compare Check Point Software Technologies Ltd (CHKP) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Illumina, Inc. — how do they compare? Check Point Software Technologies Ltd trades at $132.94 (market cap $13.97B), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Illumina, Inc. is far larger — about 2.1× Check Point Software Technologies Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | ILMN | |
|---|---|---|
Market Cap | $13.97B | $28.93B |
Sector | Technology | Health |
52-Week High | $223.00 | $194.33 |
52-Week Low | $112.47 | $91.00 |
Enterprise Value | $13.17B | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHKP trades at $134.32, up 1.99% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 38.37% net income margin and trades at a P/E of 13.82. Recent news highlights AI security partnerships and upcoming Q2 2026 earnings on July 30, 2026.
Outlook is mixed: analyst consensus targets $148.43 (10.5% upside) with 46% buy ratings, but technicals and insider sales pose risks. Key catalysts include AI integration progress and earnings results, while competition and sector volatility remain headwinds.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
